According to the results of the APRIL study, in which the Hospital de Bellvitge and IDIBELL have participated, ApTOLL has shown good safety in 151 patients with acute ischemic stroke.
A new neuroprotective drug shows good preliminary results for ischemic stroke Read More »
In 2022, with almost 1,500 published articles, of which almost 600 were led by IDIBELL researchers, our research maintained its high level of quality and excellence, with an average impact factor greater than nine.
Two studies led by IDIBELL and the Catalan Institute of Oncology show that DNA sequencing in these samples can detect endometrial cancer, which would avoid much more invasive and painful methods.
RINT1 mutations would be causing a deregulation of fat metabolism and intracellular communication of energy production. This is a significant advance in the understanding of this disease, and opens new perspectives for diagnosis and possible treatment in the future.
The application will monitor in real-time and, combined with neuroimaging studies, will allow the identification of new biomarkers to predict the disease evolution.
New collaboration with Blue Zone Studio to create an OCD monitoring application Read More »
A team of researchers including scientists from the Bellvitge Campus, has made a map of lesions of different nature related to epilepsy and discovered that the alteration of a specific neural circuit was common to all the lesions studied.
Study of brain lesions reveals key connections in epilepsy Read More »
Treatment with L-Ergothioneine manages to increase the solubility of cystine in urine, thus preventing the formation of stones or delaying their appearance. After treatment, an improvement in the oxidative status and mitochondrial function in the kidney is also observed. If these results are validated in future clinical trials, a new preventive treatment for this disease would be available.
In the two published studies, the scientific team uses the intestine organoid as a model, a three-dimensional structure similar to mini-intestines created in the laboratory from stem cells. Deciphering the functioning of some transcription factors in the formation of the intestine has been the objective of the team.
Valle de la Riva, President of the Foundation, gave the check to Mònica Povedano, IDIBELL researcher and neurologist at the Hospital de Bellvitge, during the first day of the Puig Vela Clássica.
La Fundación Vela Clásica de España donates 20,000 euros for ALS Research Read More »
A collaboration has been signed between the Bellvitge Biomedical Research Institute (IDIBELL), the Institute of Cancer Research (ICR) in London, and Vivan Therapeutics to jointly develop molecules that recognize more than one target for personalized treatment of colorectal cancer.
